Medical Devices

24 tickers rated Buy in this theme
NewestHighest Score Ranks all matching reports in this category by score, highest first.
Alcon Inc.
ALC·Healthcare
A ★★★★Buy
Current$71.83
Target$82.74
Return+15.2%
Nov 13, 2026

Alcon offers durable global eye-care demand, improving cash generation and a discounted historical valuation, but U.S. implant competition and weak reported capital efficiency could limit earnings growth.

Score
81
Globus Medical, Inc.
GMED·Healthcare
A ★★★★Buy
Current$71.05
Target$92.65
Return+30.4%
Nov 8, 2026

Globus Medical offers an attractive valuation backed by strong cash flow and a differentiated spine surgery ecosystem, but sustained upside depends on stabilizing Nevro demand and restoring underlying revenue growth.

Score
82
Zoetis Inc.
ZTS·Healthcare
A ★★★★Buy
Current$79.40
Target$99.75
Return+25.6%
Nov 8, 2026

Zoetis offers a potentially attractive recovery opportunity through its leading animal-health franchise, strong cash generation, and compressed valuation, although U.S. veterinary demand weakness and dermatology competition threaten future earnings growth.

Score
78
Mettler-Toledo International Inc.
MTD·Healthcare
A ★★★★Buy
Current$1,722.15
Target$1,590.00
Return-7.7%
Nov 8, 2026

Mettler-Toledo combines exceptional capital efficiency, durable precision-instrument franchises, and consistent cash generation, but its premium valuation requires sustained earnings growth and offers limited downside protection.

Score
77
Insulet Corporation
PODD·Healthcare
A ★★★★Buy
Current$146.51
Target$170.94
Return+16.7%
Nov 7, 2026

Insulet combines recurring Omnipod revenue, strong international growth, and improving profitability with a sharply compressed valuation, although intensifying insulin pump competition and weaker cash conversion threaten future returns.

Score
83
Smith & Nephew plc
SNN·Healthcare
A ★★★★Buy
Current$31.15
Target$37.12
Return+19.2%
Nov 7, 2026

Smith & Nephew offers an attractive medical-device recovery opportunity supported by strong sports medicine franchises and improving cash generation, although persistent US orthopedic weakness and reimbursement pressure threaten execution.

Score
80
Envista Holdings Corporation
NVST·Healthcare
A ★★★★Buy
Current$25.17
Target$28.00
Return+11.2%
Nov 7, 2026

Envista offers a dental-products turnaround supported by improving margins, resilient cash generation, and reasonable valuation, although elective-procedure cyclicality and intense competition could limit the recovery.

Score
76
STERIS plc
STE·Healthcare
A ★★★★Buy
Current$252.30
Target$272.80
Return+8.1%
Nov 7, 2026

STERIS combines recurring infection-prevention revenue, specialized sterilization infrastructure, and durable healthcare demand, but its premium cash-flow valuation and debt-financed Xodus acquisition constrain near-term upside.

Score
75
Zimmer Biomet Holdings, Inc.
ZBH·Healthcare
A ★★★★Buy
Current$105.59
Target$117.65
Return+11.4%
Nov 7, 2026

Zimmer Biomet offers durable orthopedic demand, strong cash generation, and recovery potential at modest forward earnings multiples, but knee weakness, acquisition leverage, and uncertain robotics returns constrain upside.

Score
79
Henry Schein, Inc.
HSIC·Healthcare
A ★★★★Buy
Current$85.31
Target$98.60
Return+15.6%
Nov 6, 2026

Henry Schein offers a healthcare distribution earnings-recovery opportunity supported by share gains, margin expansion, and buybacks, although elevated leverage and modest returns on invested capital constrain its upside.

Score
75
Fresenius Medical Care AG
FMS·Healthcare
A ★★★★Buy
Current$23.66
Target$26.40
Return+11.6%
Nov 6, 2026

Fresenius Medical Care offers durable dialysis demand, strong free cash flow, and buyback-supported earnings recovery at a modest valuation, although reimbursement pressure, weak treatment volumes, and restructuring execution remain significant risks.

Score
77
IDEXX Laboratories, Inc.
IDXX·Healthcare
A ★★★★Buy
Current$698.55
Target$653.60
Return-6.4%
Nov 5, 2026

IDEXX combines a deeply integrated veterinary diagnostics ecosystem with exceptional cash generation and recurring revenue growth, but its substantial valuation premium leaves investors exposed to slower testing demand or earnings growth.

Score
78